deferasirox has been researched along with Aplasia Pure Red Cell in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujisawa, S; Kanamori, H; Machida, S; Mori, T; Nakaseko, C; Ohwada, C; Okamoto, S; Onizuka, M; Onoda, M; Saito, T; Sakaida, E; Shimizu, R; Shono, K; Takahashi, S; Takeuchi, M; Tanaka, M; Toyosaki, M; Usuki, K; Yano, S | 1 |
| Ando, K; Kojima, M; Machida, S; Miyamoto, M; Moriuchi, M; Ohbayashi, Y; Sato, A | 1 |
| Hayakawa, F; Naoe, T; Tomita, A | 1 |
3 other study(ies) available for deferasirox and Aplasia Pure Red Cell
| Article | Year |
|---|---|
Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Allografts; Child; Deferasirox; Disease-Free Survival; Erythrocyte Transfusion; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Iron Overload; Male; Middle Aged; Red-Cell Aplasia, Pure; Survival Rate | 2019 |
Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.
Topics: Benzoates; Deferasirox; Erythrocyte Transfusion; Erythropoiesis; Female; Humans; Iron Chelating Agents; Middle Aged; Red-Cell Aplasia, Pure; Treatment Outcome; Triazoles | 2013 |
Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome.
Topics: Acute Disease; Administration, Oral; Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Triazoles | 2014 |